The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." ...

Louis School of Medicine explore HER2-low breast cancer ... is currently facing a paradigm shift in both the definition of HER2 status and in the existing treatment algorithms.” ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...

As more women are found to have low HER2 expression breast cancer, they may benefit from the newer targeted therapies being studied and used to treat patients with HER2-positive breast cancer.

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with AstraZeneca ...

while the DESTINY-Breast06 trial highlighted the efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancer. Additional highlights included a phase 2 HER3-DXd antibody-drug conjugate ...

T-DXd also has demonstrated efficacy in the newly minted category of HER2-low breast cancer. Post-hoc analyses of KATHERINE showed the greatest effect of T-DM1 on tumors with high-level expression ...